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LETTERS TO THE EDITOR
Lack of Genetic and Epigenetic Changes in CDKN2A in
Melanocytic Nevi
To the Editor:
The strongest known epidemiologic risk factor for melanoma is a
large number of melanocytic nevi (Swerdlow and Green, 1987),
whereas the most important genetic risk factor is germline mutation
of the CDKN2A gene, which encodes the cell cycle inhibitor p16
(Kamb et al, 1994; Nobori et al, 1994). CDKN2A mutations exist
in some melanoma-prone families (reviewed in Hayward, 1996;
Foulkes et al, 1997; Ruas and Peters, 1998), but account for only a
small fraction of all familial melanoma (Platz et al, 1997; Aitken et al,
1999).
Some melanoma kindreds include individuals with a high
prevalence of ``dysplastic'' (Greene et al, 1985) or ``atypical''
(Gruis et al, 1995) nevi, but this phenotype does not segregate with
CDKN2A (reviewed in Hayward, 1996); however, evidence for
linkage of ``common'' nevus count with CDKN2A has been found
in three melanoma pedigrees, only one of which carried an exonic
mutation, suggesting that other variants in the region, outside the
sequence encoding p16, affect nevus density (Cannon-Albright et al,
1994). We have shown by sib-pair linkage analysis that ±30% of
variance in moliness is due to genetic variation at or close to the
marker D9S942 (Zhu et al, 1999), 15 kilobases upstream of
CDKN2A, and we surmise that D9S942 is in disequilibrium with a
functional polymorphism nearby. We hypothesize that as germline
mutations in the exons of CDKN2A are rare, it is likely that
variants in the noncoding regions of this gene are responsible for
this major determinant of nevi, and by inference, of melanoma.
Somatic changes and loss of heterozygosity (LOH) of CDKN2A
support a role for this gene in nevus etiology (Healy et al, 1996a;
Lee et al, 1997). Given the above links between CDKN2A,
melanoma, and nevi, we looked for chromosomal loss, structural
and epigenetic changes in the CDKN2A gene in benign
melanocytic lesions.
A 4 mm punch was used to separate neval from stromal
tissue from 10 g paraf®n-embedded sections of 25 intradermal
nevi and 25 compound nevi. Sections of nevi and stroma were
incubated in 80 ml of lysis buffer (10 mM Tris-HG, pH 8.3;
50 mM KCl; 2.5 mM MgCl2) plus 4.4 ml of 10 mg per ml
proteinase K and 4 ml of 10% Tween 20. Samples were
incubated at 55°C for 18±48 h then boiled for 15 min, adjusted
to 1 mM EDTA, and centrifuged for 1 min at 2300 3 g. LOH
at CDKN2A was assessed by comparing genotypes at D9S942
as previously described (Pollock et al, 1998).
CDKN2A was screened for mutations in nevus samples using
SSCP analysis as described (Aitken et al, 1999). Samples that
showed aberrant band mobility were re-ampli®ed and run on a 2%
agarose gel. Appropriate fragments were excised and puri®ed by
passing them through a QiaQuick (Qiagen) gel extraction column,
then 50±250 ng were sequenced as described (Aitken et al, 1999).
Matching stromal DNA was analyzed when variants were detected.
The CpG island domain of CDKN2A, encompassing the
promotor and exon 1 (nucleotides 28602±28856 in GenBank
entry AC000048), was screened for methylation using the bisul®te
sequencing method under conditions described in Clark et al
(1994). The control primers used for the standard bisul®te p16
ampli®cation were: outer, p16±4 (28844±28819) and p16±6
(28602±28579), and inner, p16±4 and p16±5 (28516±28541)
(Huschtscha et al, 1998). The MSP-PCR p16 primers were:
outer, p16CG-4 (28962±28939) and p16CG-6 (28641±28616), and
inner, p16CG-4 and p16CG-5 (28880±28856); sequence coordi-
nates are from GenBank entry AC000048. Reaction conditions for
the standard bisul®te polymerase chain reaction (PCR) and
methylation-speci®c primers PCR (MSP-PCR) were as described
(Huschtscha et al, 1998).
DNA was successfully extracted from 45 pairs of specimens, of
which 41 were constitutionally heterozygous for D9S942. In all
nevus samples bands corresponding to each allele were seen at equal
intensity to matching somatic DNA, indicating no LOH. No nevus
had acquired a somatic change in the protein-coding region of
CDKN2A, although four individuals carried germline CDKN2A
variants. Individual 22 was homozygous for the nucleotide 442 G
to A variant (ala148thr), and individuals 29 and 43 were hetero-
zygous for this polymorphism. One case possessed a heterozygous
nucleotide 412 A to G mutation (arg138gly) (Fig 1). To our
knowledge this is the ®rst report of an individual with a germline
CDKN2A mutation who does not have melanoma or a family
history of melanoma.
No hypermethylation of the CDKN2A promoter, which might
lead to loss of p16 expression in the nevus samples, could be
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Figure 1. Autoradiograph of a representative SSCP gel showing
aberrant band mobility for exon 2 of CDKN2A. Lane 1, sample 21
(heterozygous for arg138gly mutation); lane 2, sample 22 (homozygous
for ala148thr polymorphism); lanes 3±7 and 9, control samples
(homozygous for wildtype alleles); lane 8, sample 29 (heterozygous for
ala148thr polymorphism).
detected in any of the 40 nevi tested, either by TaqI digestion
(Fig 2a) or by MSP-PCR (Fig 2b).
Our results suggest little or no involvement of genetic or
epigenetic alterations of CDKN2A in nevus etiology, and thus
support the data of others who have failed to detect CDKN2A
mutation (Healy et al, 1996b) or methylation (Gonzalgo et al, 1997)
in various types of nevi; however, our ®ndings do not rule out
mutations in noncoding regions nor factors other than methylation
affecting expression of this gene. Alternatively, variations in
noncoding regions of CDKN2A or in a gene adjacent to
CDKN2A may account for the variance in nevus count we have
shown to be linked to this region (Zhu et al, 1999).
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Real-Time Evidence of In Vivo Leukocyte Traf®cking in
Human Skin by Re¯ectance Confocal Microscopy
To the Editor:
The dynamic sequence of events mediating leukocyte emigration
from vascular to tissue compartments, including lymphocyte
homing and localization of monocytes and neutrophils in in¯amed
tissue, is directed by adhesive molecules and molecular signals that
result in the attachment/rolling of leukocytes followed by their
strong adhesion/arrest and diapedesis (Sackstein et al, 1988; Shimizu
et al, 1992; Springer, 1994; Clark and Brugge, 1995; Sackstein,
1995). To date, this multistep process has been investigated utilizing
in vitro and in vivo experimental models requiring invasive
procedures such as multiple biopsies to allow ex vivo histologic
analysis of emigrated leukocytes and, more recently, by intravital
Figure 2. Methylation analysis of the p16 promoter region. (A)
DNA from nevus samples (1±9) was bisul®te-treated and ampli®ed with
primers that amplify methylated and unmethylated DNA in proportion.
The PCR was either undigested (U) or digested with TaqI (C).
Methylated p16 DNA was ampli®ed as a control from bisul®te-treated
human DNA that had been spiked at 10%, 25%, and 50% levels
(Warnecke et al, 1997). Lane M; DNA size markers. (B) DNA from
nevus samples (1±16) was bisul®te-treated and ampli®ed using MSP-
PCR primers. Methylated p16 DNA was ampli®ed as a control from
bisul®te-treated human DNA that had been spiked at 0.1% (+) and 1%
(++) and not spiked as a negative control (±).
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